clinical bleeding was not evaluated [3] . However, subsequent studies assessing the value of correcting the prolonged BT with desmopressin in patients with cirrhosis gave positive re sults [4, 5] , thus supporting the hypothesis that the BT may play a role. On the other hand, studies with clinical end points that assessed the risk of bleeding after desmopressin infusion and BT shortening gave negative results [6, 7] , thus casting doubts on the value of the BT prolongation in predicting the risk of bleeding. Furthermore, in a recent study of plate let adhesion in cirrhosis assessed under flow conditions, Lis man et al. [8] , found that highly elevated levels of von Wille brand factor, which are typically found in patients with cir rhosis, contribute to the induction of primary hemo stasis. Accordingly, increased von Willebrand factor may compen sate for the defect of platelet numbers and functions in these patients [8] .
So that, we may conclude that although defects of primary hemo stasis in cirrhotics may have a causative role in the occur rence of bleeding, the BT once regarded as the test of choice to investigate primary hemo stasis is probably not predictive of bleeding and should be abandoned. The logical conclu sion is that if one wishes to rely on laboratory testing for pri mary hemo stasis to predict bleeding in chronic liver disease methods should go beyond the BT. Results from the litera ture showed also little clinical value on the use of such other surrogate tests for the BT in this setting as the platelet func tion assay.
Fibrinolysis
The literature and text books describe that cirrhosis is char acterized by hyperfibrinolysis and that this complex defect can be documented in plasma through global fibrinolytic tests or through the measurement of the individual components [1] . However, the measurement of the individual components Hemostasis abnormalities in liver cirrhosis: myth or reality?
in cirrhosis [13] . Interestingly, the balance of pro and anti coagulants in cirrhosis was found to be normal when assessed as thrombin generation monitored over time in the presence of thrombomodulin [13] . This happened notwithstanding that PT and APTT were prolonged [13] . Platelets are impor tant contributors to the generation of thrombin [14] . Hence, the occurrence of thrombocytopenia and/or thrombocytop athy in patients with cirrhosis may at least in theory affect thrombin generation in these patients. A recent study showed that thrombin generation in the presence of thrombomodulin when measured in platelet rich plasma from patients with cir rhosis was indistinguishable from that of healthy subjects un der the same experimental conditions, provided that the num bers of platelets were higher than 60 × 10 9 /l [15] . The tentative conclusion stemming from these studies is that coagulation in patients with liver cirrhosis is normal provided that the numbers of platelets are sufficiently high to sustain the normal thrombin generation elicited by plasma. This conclusion might explain the poor efficacy of such proco agulant agents as activated factor VII when used for patients with chronic liver disease [16 18 ] and may justify clinical tri als to see whether platelets transfusion or treatment with re combinant human thrombopoietin [19] are effective in those patients with severe thrombocytopenia when they bleed spon taneously or when they undergo such risky procedures as sur gery or liver bio psy.
SUMMARY
Although not yet conclusive all the above observations are consistent with the concept that the abnormality of hemo stasis in stable chronic liver disease is more a myth than a re ality and that the culprits for the bleeding problems occa sionally seen in these patients should be searched elsewhere. Together with severe thrombocytopenia other potential can didates responsible for bleeding are the hemo dynamic alter ations subsequent to portal hypertension, endothelial dys function (reduced vascular tone), bacterial infections and re nal failure [1] . Interventions aimed at correcting these altera tions might be more effective to stop bleeding than correcting the hemo static derangement. cannot give us a clear picture of the balance of fibrinolysis be cause of the complex balance where there are activators and anti activators which regulate the conversion of plasmino gen to plasmin. As a matter of fact reports from the litera ture show that cirrhotics may have increased levels of tissue plasminogen activator and its inhibitor, but also decreased levels of plasminogen, anti plasmin and factor XIII [1] . Re cently, attention has also been put on thrombin activatable fi brinolysis inhibitor (TAFI). Research workers speculated that its deficiency may explain the hyperfibrinolytic state often described in cirrhosis. Two recent studies on this topic gave conflicting results. According to Lisman et al. [9] , deficien cy of TAFI is not associated with increased plasma fibrinol ysis because the reduction of profibrinolytic factors is coun terbalanced by the concomitant reduction of antifibrinolytic factors. Whereas, according to Colucci et al. [10] , the defi ciency of TAFI is associated with increased plasma fibrinoly sis. The explanation for these conflicting results rests proba bly on the different assay design used by the two investigators to assess the balance of fibrinolysis.
In conclusion, the role played by hyperfibrinolysis in the oc currence of bleeding in cirrhotics is still unclear and the mea surement of individual components of the fibrinolytic pathway is unlikely to help. Simple global tests representing the bal ance operating in vivo should be developed and investigated in clinical trials.
Coagulation
Chronic liver disease is characterized by an impaired synthe sis of coagulation factors [11] . This complex defect is conven tionally documented through the measurement of individual coagulation factors, or through the prolongation of such glob al tests as the prothrombin time (PT) and the activated partial thromboplastin time (APTT). On the other hand, it is known that global tests are not predictive of bleeding in patients with cirrhosis [12] . Recently, it has been surmised that glob al tests such as PT and APTT might be inadequate to reflect the balance as it occurs in vivo especially in cirrhosis, a condi tion where the naturally occurring anticoagulants protein C, antithrombin and tissue factor pathway inhibitor are reduced in para llel with procoagulants. Furthermore, protein C in vit ro is activated to a limited extent in the absence of trombo modulin and therefore it cannot exert its full anticoagulant ac tivity [13] . It should be noted that plasma and reagents need ed to perform PT and APTT do not contain thrombomodu lin. Therefore, it is reasonable to assume that PT and APTT are responsive only to the thrombin generated as a function of procoagulants, but much less to the inhibition of throm bin mediated by the anticoagulants. According to this con cept PT and APTT should be regarded as suitable tests to in vestigate congenital deficiency of procoagulants (conditions where the anticoagulants are normal), but they are unsuitable to investigate congenital deficiency of anticoagulants or ac quired deficiency of both pro and anti coagulants as it occurs
